Cancer treatment and survivorship statistics, 2014
Carol DeSantis,Chun Chieh Lin,Angela B. Mariotto,Rebecca L. Siegel,Kevin Stein,Joan L. Kramer,Rick Alteri,Anthony S. Robbins,Ahmedin Jemal +8 more
Reads0
Chats0
TLDR
The number of cancer survivors continues to increase due to the aging and growth of the population and improvements in early detection and treatment, and current treatment patterns for the most common cancer types are described based on information in the National Cancer Data Base and the SEER and SEER‐Medicare linked databases.Abstract:
The number of cancer survivors continues to increase due to the aging and growth of the population and improvements in early detection and treatment. In order for the public health community to better serve these survivors, the American Cancer Society and the National Cancer Institute collaborated to estimate the number of current and future cancer survivors using data from the Surveillance, Epidemiology, and End Results (SEER) program registries. In addition, current treatment patterns for the most common cancer types are described based on information in the National Cancer Data Base and the SEER and SEER-Medicare linked databases; treatment-related side effects are also briefly described. Nearly 14.5 million Americans with a history of cancer were alive on January 1, 2014; by January 1, 2024, that number will increase to nearly 19 million. The 3 most common prevalent cancers among males are prostate cancer (43%), colorectal cancer (9%), and melanoma (8%), and those among females are cancers of the breast (41%), uterine corpus (8%), and colon and rectum (8%). The age distribution of survivors varies substantially by cancer type. For example, the majority of prostate cancer survivors (62%) are aged 70 years or older, whereas less than one-third (32%) of melanoma survivors are in this older age group. It is important for clinicians to understand the unique medical and psychosocial needs of cancer survivors and to proactively assess and manage these issues. There are a growing number of resources that can assist patients, caregivers, and health care providers in navigating the various phases of cancer survivorship.read more
Citations
More filters
Journal ArticleDOI
Cancer treatment and survivorship statistics, 2016.
Kimberly D. Miller,Rebecca L. Siegel,Chun Chieh Lin,Angela B. Mariotto,Joan L. Kramer,Julia H. Rowland,Kevin Stein,Rick Alteri,Ahmedin Jemal +8 more
TL;DR: The number of cancer survivors continues to increase because of both advances in early detection and treatment and the aging and growth of the population and for the public health community to better serve these survivors, the American Cancer Society and the National Cancer Institute collaborate to estimate the number of current and future cancer survivors.
Journal ArticleDOI
Breast Cancer Screening for Women at Average Risk: 2015 Guideline Update From the American Cancer Society
Kevin C. Oeffinger,Elizabeth T. H. Fontham,Ruth Etzioni,Abbe Herzig,James S. Michaelson,Ya Chen Tina Shih,Louise C. Walter,Timothy R. Church,Christopher R. Flowers,Samuel J. LaMonte,Andrew M.D. Wolf,Carol DeSantis,Joannie Lortet-Tieulent,Kimberly S. Andrews,Deana Manassaram-Baptiste,Debbie Saslow,Robert A. Smith,Otis W. Brawley,Richard C. Wender +18 more
TL;DR: The updated ACS guidelines for breast cancer screening for women at average risk of breast cancer provide evidence-based recommendations and should be considered by physicians and women in discussions about breast cancer Screening.
Journal ArticleDOI
Nanoparticle Probes for the Detection of Cancer Biomarkers, Cells, and Tissues by Fluorescence
Alyssa B. Chinen,Chenxia M. Guan,Jennifer R. Ferrer,Stacey N. Barnaby,Timothy J. Merkel,Chad A. Mirkin +5 more
TL;DR: Overcoming Limitations in Nanoparticle Drug Delivery: Triggered, Intravascular Release to Improve Drug Penetration into Tumors and Design Considerations for Tumour-Targeted Nanoparticles.
Journal ArticleDOI
American Cancer Society/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline
Carolyn D. Runowicz,Corinne R. Leach,N. Lynn Henry,Karen S. Henry,Heather T. Mackey,Rebecca Cowens-Alvarado,Rachel S. Cannady,Mandi Pratt-Chapman,Stephen B. Edge,Linda A. Jacobs,Arti Hurria,Lawrence B. Marks,Samuel J. LaMonte,Ellen Warner,Gary H. Lyman,Patricia A. Ganz +15 more
TL;DR: Recommendations on surveillance for breast cancer recurrence, screening for second primary cancers, assessment and management of physical and psychosocial long-term and late effects of breast cancer and its treatment, health promotion, and care coordination/practice implications are made.
Journal ArticleDOI
Tumor Microbiome Diversity and Composition Influence Pancreatic Cancer Outcomes
Erick Riquelme,Erick Riquelme,Yu Zhang,Liangliang Zhang,Maria Fernanda Montiel,Michelle Zoltan,Wenli Dong,Pompeyo R. Quesada,Ismet Sahin,Vidhi Chandra,Anthony San Lucas,Paul Scheet,Hanwen Xu,Samir M. Hanash,Lei Feng,Jared K. Burks,Kim Anh Do,Christine B. Peterson,Deborah Nejman,Ching Wei D. Tzeng,Michael P. Kim,Cynthia L. Sears,Nadim J. Ajami,Joseph F. Petrosino,Laura D. Wood,Anirban Maitra,Ravid Straussman,Matthew H.G. Katz,James R. White,Robert R. Jenq,Jennifer A. Wargo,Florencia McAllister +31 more
TL;DR: This study demonstrates that PDAC microbiome composition, which cross-talks to the gut microbiome, influences the host immune response and natural history of the disease.
References
More filters
Journal ArticleDOI
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma.
F. Stephen Hodi,Steven J. O'Day,David F. McDermott,R. W. Weber,Jeffrey A. Sosman,John B. A. G. Haanen,Rene Gonzalez,Caroline Robert,Dirk Schadendorf,Jessica C. Hassel,Wallace Akerley,Alfons J.M. van den Eertwegh,Jose Lutzky,Paul Lorigan,Julia Vaubel,Gerald P. Linette,David W. Hogg,Christian H. Ottensmeier,Céleste Lebbé,Christian Peschel,Ian Quirt,Joseph I. Clark,Jedd D. Wolchok,Jeffrey S. Weber,Jason Tian,Michael Yellin,Geoffrey M. Nichol,Axel Hoos,Walter J. Urba +28 more
TL;DR: Ipilimumab, with or without a gp100 peptide vaccine, as compared with gp100 alone, improved overall survival in patients with previously treated metastatic melanoma.
Journal ArticleDOI
Cancer statistics, 2014
TL;DR: The magnitude of the decline in cancer death rates from 1991 to 2010 varies substantially by age, race, and sex, ranging from no decline among white women aged 80 years and older to a 55% decline among black men aged 40 years to 49 years.
Journal ArticleDOI
Mutations of the BRAF gene in human cancer
Helen Davies,Graham R. Bignell,Charles Cox,Philip J. Stephens,Sarah Edkins,S. M. Clegg,Jon W. Teague,Hayley Woffendin,Mathew J. Garnett,William Bottomley,Neil Davis,Ed Dicks,Rebecca Ewing,Yvonne Floyd,Kristian Gray,S. Hall,Rachel Hawes,Jaime Hughes,Vivian Kosmidou,Andrew Menzies,Catherine Mould,Adrian Parker,Claire Stevens,Stephen Watt,Steven Hooper,Rebecca Wilson,Hiran Jayatilake,Barry A. Gusterson,Colin Cooper,Janet Shipley,Darren Hargrave,Kathy Pritchard-Jones,Norman J. Maitland,Georgia Chenevix-Trench,Gregory J. Riggins,Darell D. Bigner,Giuseppe Palmieri,Antonio Cossu,Adrienne M. Flanagan,Andrew G. Nicholson,Judy W. C. Ho,Suet Yi Leung,Siu Tsan Yuen,Barbara L. Weber,Hilliard F. Seigler,Timothy L. Darrow,Hugh Paterson,Richard Marais,Christopher J. Marshall,Richard Wooster,Michael R. Stratton,P. Andrew Futreal +51 more
TL;DR: BRAF somatic missense mutations in 66% of malignant melanomas and at lower frequency in a wide range of human cancers, with a single substitution (V599E) accounting for 80%.
National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology
DG Pfister,K. K. Ang,D Brizel +2 more
Journal ArticleDOI
Sipuleucel-T immunotherapy for castration-resistant prostate cancer.
Philip W. Kantoff,Celestia S. Higano,N. Shore,E. Roy Berger,Eric J. Small,David F. Penson,Charles H. Redfern,Anna C. Ferrari,Robert Dreicer,Robert B. Sims,Yi Xu,Mark W. Frohlich,Paul F. Schellhammer +12 more
TL;DR: The use of sipuleucel-T prolonged overall survival among men with metastatic castration-resistant prostate cancer and immune responses to the immunizing antigen were observed in patients who received sipuleUcel- T.